Danielle Jones, CMHC | |
110 N Main St, Camden, DE 19934-1232 | |
(302) 401-9788 | |
Not Available |
Full Name | Danielle Jones |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 110 N Main St, Camden, Delaware |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679151427 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
101YM0800X | Counselor - Mental Health | PC-0011508 (Delaware) | Primary |
Mailing Address | Practice Location Address |
---|---|
Danielle Jones, CMHC 374 Winnow Dr, Clayton, DE 19938-3531 Ph: (302) 401-9788 | Danielle Jones, CMHC 110 N Main St, Camden, DE 19934-1232 Ph: (302) 401-9788 |
News Archive
A multidisciplinary international team of scientists solved the mystery of a recently discovered type of controlled cell death, mapping the path to potential therapies for conditions ranging from radiation injury to cancer.
At the 2009 Radiological Society of North America Annual Meeting (RSNA 2009), Canon U.S.A., Inc., a leader in digital advanced imaging technologies (Booth #8339), will showcase the Canon imagePRESS C1+ digital printing solution with Virtual Imaging's CYPHER, which is a DICOM printer server, a DICOM print solution which has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) .
A molecular "recycling plant" permits nerve cells in the brain to carry out two seemingly contradictory functions - changeable enough to record new experiences, yet permanent enough to maintain these memories over time.
Patients who had access to GP surgeries with longer opening times in evenings and at weekend visited accident and emergence departments far fewer times than those who did not have similar access to primary care.
Researchers at the Cleveland Clinic Lou Ruvo Center for Brain Health have conducted the first-ever analysis of clinical trials for Alzheimer's disease (AD), revealing an urgent need to increase the number of agents entering the AD drug development pipeline and progressing successfully towards new therapy treatments.
› Verified 1 days ago